Research programme: glaucoma therapeutic - SK Biopharmaceuticals/AriBio

Drug Profile

Research programme: glaucoma therapeutic - SK Biopharmaceuticals/AriBio

Alternative Names: SKL-G

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK biopharmaceuticals
  • Developer AriBio; SK biopharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Glaucoma

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glaucoma in South Korea
  • 03 Jul 2013 SK Biopharmaceuticals and AriBio agree to co-develop SKL-G for Glaucoma
  • 03 Jul 2013 SKL-G is available for licensing as of 03 Jul 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top